RPS29P30

Across TCGA pan-cancer cohorts, RPS29P30 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated RPS29P30 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RPS29P30 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RPS29P30 expression acts as an unfavorable survival marker.

LIHC, BRCA, and ESCA are the cancer types where RPS29P30 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.028	0.777	<.001	72	view →
BRCA	DFS	Tertile	All	0.178	0.528	.011	60	view →
ESCA	OS	Tertile	All	0.171	0.704	<.001	54	view →
STAD	DFS	Tertile	All	0.357	0.664	.003	51	view →
KIRC	DFS	Tertile	IV	0.127	0.619	.008	36	view →
UCS	OS	Tertile	All	0.153	0.687	.019	18	view →
CESC	DFS	Tertile	All	0.191	0.823	<.001	18	view →
SARC	OS	Tertile	All	0.174	0.860	<.001	18	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

RPS29P30–LIHC (OS)

Open the LIHC breakdown →